Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + pexmetinib
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Ipilimumab + pexmetinib is an investigational combination therapy for advanced solid tumors, including melanoma, kidney cancer, and non-small cell lung cancer. Ipilimumab is a monoclonal antibody that acts as a checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), thereby enhancing immune responses against tumor cells. Pexmetinib (ARRY-614) is an orally bioavailable small-molecule inhibitor of p38 MAP kinase and Tie2 kinase with antineoplastic, anti-inflammatory, and antiangiogenic activities. By inhibiting these kinases, pexmetinib may reduce pro-inflammatory cytokine production and tumor angiogenesis while promoting tumor cell death. The combination aims to leverage both immune activation via CTLA-4 blockade and direct inhibition of tumor-promoting pathways through kinase inhibition[1][5][7][9].
- Brand names
- Yervoy
- Other names
- ipilimumab + ARRY-614
02
Targets
SFK (SRC family kinases)TEK (Tie2)MAPK14 (p38 mitogen-activated protein kinase alpha)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on ipilimumab + pexmetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + pexmetinib.